Daniel Friedman
Managing Director BroadOak Capital
Daniel Friedman is a Managing Director on BroadOak’s growth capital investing team where he specializes in portfolio management and investment execution. Prior to joining BroadOak in 2019, Daniel worked for Raymond James within the Life Sciences Investment Banking team where he focused on public financings and M&A for biotechnology and medical device companies.
Daniel currently serves as a director on the boards of PBS Biotech and Precision Cell Systems, as well as acting as an observer at Pluristyx and Biolog. Daniel previously acted as a board observer at Avidien Technologies and antibodies-online.
Seminars
With iPSC therapies facing high upfront costs, complex manufacturing demands, and evolving investor sentiment, early alignment across pharma, VCs, and funding stakeholders is critical. This panel will explore how to strategically de-risk clinical development, secure funding, and build commercially viable cell therapy programs in a capital-intensive landscape.
- How to engage pharma BD, VCs, and payers early to overcome the “elephant in the room”, high cost of goods and long development timelines
- What investors look for in scalable, robust iPSC manufacturing strategies before committing capital
- Coordinating government funding, venture investment, and pharma partnerships to support sustainable clinical and commercial success
